Shanghai issues first standard for plant-derived exosome nanovesicles

Shanghai has released a new group standard for plant-derived exosome-like nanovesicles, setting baseline purity and concentration requirements for a fast-growing raw material used in cosmetics, medical devices and specialized nutrition. The guideline is meant to give manufacturers a shared technical reference as China’s interest in natural nanomaterials accelerates.

Why it matters: - The standard gives China’s PELNV sector its first shared technical framework for quality, testing and industrial production. - Purity and concentration benchmarks can make product registration, filings and downstream manufacturing more consistent. - The guideline targets a material that sits at the center of growing demand for natural ingredients in skincare, wound care and specialized nutrition.

What happened: - The Shanghai Yangtze River Delta Medical Device Industry Promotion Association released group standard T/SDMDA 003—2026 on July 20 in Shanghai. - The standard is titled “General Technical Guidelines for the Industrialization of Plant-Derived Exosome-Like Nanovesicles (PELNVs).” - The standard took effect Aug. 1, 2026. - Hangzhou Omni Dynamics Biotechnology Co., Ltd. served as the principal drafting organization. - The association describes the document as the first general technical standard covering the industrialization of PELNVs across the full production chain.

The details: - PELNVs are nanoscale vesicles extracted from plant material. - The vesicles have a lipid bilayer membrane. - PELNVs typically measure 30 to 500 nanometers in diameter. - PELNVs naturally carry proteins, nucleic acids and metabolites. - Researchers have studied PELNVs for their ability to transport bioactive compounds between cells. - The standard sets a minimum purity of 70 percent. - The standard sets a minimum particle concentration of 10^9 particles per milliliter. - The document covers production, testing and quality-evaluation methods. - The standard applies to four categories: cosmetics, medical devices, foods for special medical purposes and pharmaceutical development. - Dr. Qian Xueqing, chief executive of Hangzhou Omni Dynamics Biotechnology, said quality specifications for a new raw material create a common technical language for product registration and filings. - Lin Senyong, president of the Shanghai association, said the standard is meant to give the sector consistent terminology and quality-evaluation criteria. - Lin Senyong said those gaps had been a barrier to commercial adoption.

Between the lines: - The move signals a push to turn a research-heavy ingredient class into a manufacturable, registrable raw material. - The timing also reflects wider demand for naturally derived ingredients in China’s cosmetics, medical device and medical nutrition markets. - Professor Ma Gang of Shanghai Jiao Tong University said source control and batch-to-batch consistency remain central obstacles to commercial translation. - The standard is designed to address those consistency issues, which are often the difference between laboratory promise and real-world use. - At the release event, Professor Liu Yun of the Shanghai Cancer Institute presented research on anti-inflammatory activity, antioxidant effects, gut health and delivery of bioactive compounds.

What's next: - Four organizations have committed to implementing the standard in its first phase: Shanghai Runda Rongjia Biotechnology Co., Ltd.; Hangzhou Omni Dynamics Biotechnology Co., Ltd.; Shanghai Dongli Health Research Institute Co., Ltd.; and Minuo (Shanghai) Exosome Biomedicine Co., Ltd. - Hangzhou Omni Dynamics says it has built production capacity to supply raw material to manufacturers in China and abroad. - The company’s work in cosmetics, medical devices, foods for special medical purposes and pharmaceuticals remains at different stages of development. - In cosmetics, Hangzhou Omni Dynamics is preparing vesicle-based ingredients for transdermal delivery of active compounds and filing as a cosmetic raw material. - In medical devices, the company is developing dressings for acne, dermatitis and post-procedure skin recovery. - Hangzhou Omni Dynamics says it has held preliminary discussions with China’s National Medical Products Administration on a Class III drug-device combination pathway, but no regulatory application has been approved. - In foods for special medical purposes, the company is developing oral formulations intended to improve the bioavailability of compounds such as NMN and curcumin. - In pharmaceuticals, the company’s work remains at a research stage and no drug candidate has entered clinical development.

The bottom line: - Shanghai’s new standard is an early step toward making plant-derived exosome nanovesicles a more regulated, scalable industrial ingredient in China.